In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on Syros Pharmaceuticals (SYRS), with a price target of $26. The company’s shares opened today at $7.45, close to its 52-week low of $6.25.
Cann wrote:
“These preclinical data presented at the Symposium are very supportive of the ongoing phase I clinical study that includes cohorts in breast cancer. These preclinical data support the role of SY-1365 for CDK7 inhibition in HR-positive breast cancer and the potential to overcome resistance to CDK 4/6 inhibitors. In addition, the results support the hypothesis that SY-1365 is synergistic with fulvestrant, a combination that is being study in a cohort of the ongoing phase I study. We currently do not estimate that SY-1365 will impact revenue by 2022, but believe it could be an important contributor after 2022.”
According to TipRanks.com, Cann is a 4-star analyst with an average return of 4.7% and a 45.9% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Miragen Therapeutics Inc, and CytomX Therapeutics Inc.
Syros Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $20.75, implying a 178.5% upside from current levels. In a report issued on December 2, Roth Capital also maintained a Buy rating on the stock with a $14 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.86 and a one-year low of $6.25. Currently, Syros Pharmaceuticals has an average volume of 124.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyze unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations.
